The Preclinical Models of Glioma Dependent on Alternative Lenthening of Telomeres (ALT) and Current Applications
10.16476/j.pibb.2023.0033
- VernacularTitle:依赖于端粒延长替代机制的胶质瘤临床前模型及应用现状
- Author:
Jin-Kai TONG
1
;
Si-Xiang YAN
1
;
Yan-Duo ZHANG
1
;
Kai-Long HOU
1
;
Ke ZHANG
1
;
Hao-Nan ZHANG
1
;
Shun CHANG
2
;
Shu-Ting JIA
1
Author Information
1. Laboratory of Molecular Genetic of Aging & Tumor, Medical School, Kunming University of Science and Technology, Kunming 650500, China
2. Neurosurgery Department, First People’s Hospital of Yunnan Province, Kunming 650032, China
- Publication Type:Journal Article
- Keywords:
glioma;
alternative lenthening of telomere;
preclinical model
- From:
Progress in Biochemistry and Biophysics
2024;51(2):269-275
- CountryChina
- Language:Chinese
-
Abstract:
Glioma is the most common malignancy of the central nervous system, originating mainly from glial cells. Because of its highly aggressive nature, glioma has one of the highest rates of death among all types of cancer. Therefore, it is very important to develop new therapeutic approaches and drugs for glioma treatment. Instead of activate the telomerase, approximately 30% of glioma use alternative lenthening of telomere (ALT) to maintain telomere length. The mechanism of ALT development is poorly understood, however, some genetic mutations have been reported to induce the development of ALT glioma, such as ATRX, IDH1, p53, etc. The lack of ALT glioma cell lines and preclinical ALT glioma models has limited the mechanistic studies of ALT glioma. Therefore, this review listed ALT glioma cell lines that derived from primary culture or gene editing in the last decade, as well as the xenografted animal models established by ALT glioma cell lines, and discussed the role and significance these cell and animal models play in preclinical studies.
